Roivant Sciences Other accrued liabilities increased by 5.0% to $24.16M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 108.6%, from $11.58M to $24.16M. Over 3 years (FY 2021 to FY 2024), Other accrued liabilities shows a downward trend with a -5.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Significant increases may indicate rising operational costs or changes in accounting accruals.
Miscellaneous short-term obligations that do not fall into standard categories like accounts payable or debt. These ofte...
Varies widely based on company-specific accounting policies and operational structure.
other_other_accrued_liabilities_current| Q1 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.08M | $34.06M | $17.69M | $18.10M | $25.45M | $30.70M | $20.31M | $31.82M | $26.27M | $16.32M | $11.58M | $14.55M | $12.39M | $23.02M | $24.16M |
| QoQ Change | — | +99.4% | -48.1% | +2.3% | +40.6% | +20.7% | -33.9% | +56.7% | -17.4% | -37.9% | -29.0% | +25.7% | -14.8% | +85.8% | +5.0% |
| YoY Change | — | — | — | +5.9% | — | -9.8% | +14.8% | +75.8% | +3.2% | -46.8% | -43.0% | -54.3% | -52.8% | +41.1% | +108.6% |